神经药理学报

神经药理学报 ›› 2026, Vol. 16 ›› Issue (1): 58-.DOI: 10.3969/j.issn.2095-1396.2026.01.008

• 综述 • 上一篇    

碳青霉烯类耐药鲍曼不动杆菌的感染现状及耐药机制研究

刘子晔，张伟，赵建清   

  1. 1. 河北北方学院研究生学院，张家口，075000，中国 

    2. 河北北方学院附属第一医院中心实验室，张家口，075000，中国 

    3. 河北北方学院附属第一医院呼吸与危重症医学科，张家口，075000，中国

  • 出版日期:2026-03-02 发布日期:2026-05-07
  • 作者简介:刘子晔，在读硕士研究生；研究方向：呼吸与危重症医学

Current Status of Infection and Research on Resistance Mechanisms of Carbapenem-Resistant Acinetobacter Baumannii

LIU Zi-ye, ZHANG Wei, ZHAO Jian-qing   

  1. 1. Graduate School of Hebei North University, Zhangjiakou, 075000, China 

    2. Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, China 

    3. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, China

  • Online:2026-03-02 Published:2026-05-07
  • About author:

PDF (PC)

2

摘要：

近年来，随着碳青霉烯类抗生素的临床使用量增加，鲍曼不动杆菌对碳青霉烯类抗菌药物的耐药率呈逐 渐上升趋势。耐碳青霉烯类鲍曼不动杆菌目前在全球范围内广泛传播，检出率不断升高，已成为全球重大的公共 卫生问题之一。耐多药鲍曼不动杆菌的耐药机制较为复杂，涉及产碳青霉烯酶、主动外排泵的过度表达、外膜蛋 白缺失或表达改变、生物膜的形成以及药物作用位点的改变。针对耐多药鲍曼不动杆菌导致的感染，临床治疗可 选用的抗菌药物逐渐减少，感染控制难度大，患者病死率高。因此，临床应积极预防耐多药鲍曼不动杆菌感染、优 化临床抗菌药物的使用和感染防控，积极寻找新的药物及治疗方案来应对耐碳青霉烯类鲍曼不动杆菌。因此，该 文就耐碳青霉烯类鲍曼不动杆菌的感染现状及耐药机制进行综述，为后续抗生素研究、指导临床用药及预防提供 相应的科学依据。

关键词: 鲍曼不动杆菌, 碳青霉烯类耐药, 感染现状, 耐药机制

Abstract:

In recent years, with the increasing clinical use and intensity of carbapenem antibiotics, the resistance rate of Acinetobacter baumannii to carbapenem antimicrobial agents has shown a gradual upward trend. Carbapenem-resistant Acinetobacter baumannii is now widely distributed globally, with detection rates continuously rising, making it one of the major global public health issues. The resistance mechanisms of carbapenem-resistant Acinetobacter baumannii are complex, involving the production of carbapenemases, overexpression of efflux pumps, deletion or altered expression of outer membrane proteins, biofilm formation, and changes in drug binding sites. For infections caused by multidrug-resistant Acinetobacter baumannii, the number of clinically available antimicrobial agents is diminishing, making infection control challenging and resulting in high patient mortality rates. Therefore, clinicians should actively prevent multidrug-resistant Acinetobacter baumannii, optimize antimicrobial use and infection control, and actively seek new drugs and treatment strategies to address carbapenem-resistant Acinetobacter baumannii. This review summarizes the current status of infections caused by carbapenem-resistant Acinetobacter baumannii and its resistance mechanisms, providing scientific basis for future antibiotic research, clinical guidance, and prevention strategies.

Key words: acinetobacter baumannii, carbapenem resistance, infection status, resistance , mechanisms

中图分类号: